Novantrone (Mitoxantrone Hydrochloride)

Mitoxantrone Hydrochloride intercalates into DNA and locks the DNA‑topoisomerase II complex, preventing the re‑ligation of DNA strands during replication. This creates double‑strand breaks that trigger apoptosis in proliferating cells, especially malignant leukemic and prostate tumor cells. Its immunosuppressive effect also modulates inflammatory pathways, supporting its off‑label use in multiple sclerosis.

The specific dose of Novantrone is determined by the prescribing clinician based on the patient’s condition, body surface area, and treatment protocol. Dosing regimens differ between acute myeloid leukemia, metastatic prostate cancer, and off‑label multiple sclerosis indications, and must be individualized by a qualified healthcare professional.

The safety of Novantrone in pregnancy and lactation has not been established. Because the drug can cross the placenta and is excreted in breast milk, it is generally contraindicated for pregnant or nursing women. Physicians should discuss alternative therapies and advise avoidance of exposure during these periods.

To request Novantrone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Novantrone belongs to the anthracenedone class, differing from anthracyclines such as doxorubicin in its DNA intercalation and topoisomerase II inhibition profile. While both classes share cardiotoxic risk, Novantrone’s immunosuppressive properties make it useful in multiple sclerosis, a use not typical for anthracyclines. Choice of therapy depends on disease type, prior treatment history, and individual risk factors.

Novantrone should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from light and moisture. The product must be kept in a secure, temperature‑controlled environment and handled by trained personnel using aseptic techniques to maintain sterility before intravenous administration.

Novantrone is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion is typically given over a defined period, often ranging from 30 minutes to several hours, depending on the treatment protocol and patient tolerance. Monitoring during infusion includes vital signs and observation for any immediate adverse reactions.

The most serious risks of Novantrone include cardiotoxicity, which can lead to reduced left‑ventricular function, and the development of secondary, therapy‑related acute leukemia. Severe infections may also occur due to profound neutropenia, and pulmonary toxicity such as interstitial pneumonitis has been reported. Patients should be closely monitored for these events throughout therapy.

Novantrone should be avoided in patients with known severe cardiac disease, uncontrolled infections, or a history of hypersensitivity to anthracenedones. It is also contraindicated during pregnancy and breastfeeding, and in individuals with inadequate bone‑marrow reserve where further myelosuppression could be life‑threatening. Clinicians must assess each patient’s medical history before initiating therapy.